Previsioni del mercato europeo dell\'epilessia fino al 2030 - Analisi regionale - per tipo (epilessia mioclonica progressiva, epilessia riflessa, epilessia generalizzata e altro), via di somministrazione (orale, parenterale e altri), tipo di trattamento (farmaci di prima generazione, farmaci di seconda generazione e farmaci di terza generazione), fascia d\'età (adulti e bambini) e canale di distribuzione (farmacie ospedaliere, farmacie al dettaglio e altri)
I crescenti investimenti nello sviluppo di terapie per l\'epilessia guidano il mercato europeo dell\'epilessia
Il settore sanitario si sta trasformando con rapidi sviluppi tecnologici e innovazione, migliorando i servizi sanitari e la qualità delle cure. Il mercato dell\'epilessia è caratterizzato dalla presenza di numerose piccole e grandi aziende e organizzazioni che implementano varie strategie di crescita. La disponibilità di finanziamenti consente ad aziende e organizzazioni di aumentare i livelli di produzione, espandersi in nuovi mercati, investire in tecnologie nuove/migliorate e allocare più risorse alla ricerca e sviluppo. Di seguito sono menzionati alcuni degli investimenti degni di nota nel mercato dell\'epilessia, che hanno contribuito al progresso del mercato.
• A marzo 2023, il governo svedese ha deciso di commissionare a Vinnova, l\'agenzia per l\'innovazione svedese, un totale di 7,7 milioni di dollari USA (80 milioni di corone svedesi) per istituire un cluster nazionale di innovazione per la commercializzazione, lo sviluppo delle competenze e l\'aumento della capacità produttiva per terapie cellulari e altri trattamenti avanzati come la terapia genica.
• A novembre 2022, gli scienziati dell\'Università di Aston nel Regno Unito, che lavoravano a un progetto per sviluppare nuovi trattamenti farmacologici per prevenire l\'inizio dell\'epilessia infantile, hanno ricevuto 2,4 milioni di dollari USA (2 milioni di sterline) per scoprire il meccanismo della malattia nel cervello e i modi per prevenire l\'epilessia. Questo progetto triennale finanziato dal Medical Research Council è una collaborazione guidata da ricercatori del College of Health and Life Sciences dell\'Università di Aston, insieme all\'Università di Bristol e Jazz Pharmaceuticals.
• A luglio 2022, Cerebral Therapeutics si è assicurata 40 milioni di dollari nel round di finanziamento di serie C per preparare il suo trattamento per l\'epilessia mediante infusione impiantabile per lo sviluppo di fase 3. Il round di finanziamento è stato guidato da Lynx1 Capital Management tra gli altri investitori, tra cui RA Capital Management e Perceptive Advisors. Cerebral Therapeutics intende fornire i livelli specificati di valproato al sistema nervoso centrale senza causare aumento di peso, come è stato osservato nei soggetti degli studi sulla formulazione orale.
• A novembre 2021, Neurava, una startup con sede nell\'Indiana, ha ricevuto oltre 0,65 milioni di dollari in finanziamenti iniziali guidati da Elevate Ventures con la partecipazione di Purdue Foundry, UCB Biopharma, First Leaf Capital, iO Life Ventures e investitori informali. L\'azienda sta lavorando allo sviluppo di un dispositivo indossabile per monitorare e avvisare gli utenti del rischio imminente di morte improvvisa e inaspettata causata dall\'epilessia.
• A giugno 2021, Neurona Therapeutics Inc., una società di bioterapia, ha completato con successo un finanziamento di 41,5 milioni di dollari USA per far progredire la pipeline di terapie cellulari interamente di proprietà dell\'azienda, pronte all\'uso, per varie indicazioni, tra cui NRTX-1001 (uno studio clinico di fase 1/2a), una terapia cellulare neuronale inibitoria per il trattamento dell\'epilessia focale cronica.
Pertanto, l\'aumento degli investimenti nello sviluppo di trattamenti avanzati stimola la crescita del mercato dell\'epilessia.
Panoramica del mercato europeo dell\'epilessia
Il mercato europeo dell\'epilessia è suddiviso in Germania, Regno Unito, Francia, Italia, Spagna e resto d\'Europa. La regione detiene una quota di mercato significativa nel mercato dell\'epilessia. Si prevede che il mercato europeo dell\'epilessia registrerà una crescita significativa durante il periodo di previsione a causa di fattori quali la crescita significativa della popolazione anziana, le approvazioni di nuovi farmaci da parte delle autorità di regolamentazione, l\'aumento dei finanziamenti da parte dei governi per migliorare e sviluppare farmaci e trattamenti efficaci per le crisi epilettiche nella regione.
Fatturato e previsioni del mercato europeo dell\'epilessia fino al 2030 (milioni di $ USA)
Segmentazione del mercato europeo dell\'epilessia
Il mercato europeo dell\'epilessia è categorizzato in base a tipo, via di somministrazione, tipo di trattamento, fascia d\'età, canale di distribuzione e paese.
In base al tipo, il mercato europeo dell\'epilessia è categorizzato in epilessia mioclonica progressiva, epilessia riflessa, epilessia generalizzata e altro. Il segmento dell\'epilessia generalizzata ha detenuto la quota di mercato maggiore nel 2022.
In termini di via di somministrazione, il mercato europeo dell\'epilessia è categorizzato in orale, parenterale e altri. Il segmento orale ha detenuto la quota di mercato più grande nel 2022.
In base al tipo di trattamento, il mercato europeo dell\'epilessia è segmentato in farmaci di prima generazione, farmaci di seconda generazione e farmaci di terza generazione. Il segmento dei farmaci di terza generazione ha detenuto la quota di mercato più grande nel 2022.
In base alla fascia d\'età, il mercato europeo dell\'epilessia è diviso in adulti e bambini. Il segmento degli adulti ha detenuto una quota di mercato maggiore nel 2022.
In termini di canale di distribuzione, il mercato europeo dell\'epilessia è suddiviso in farmacie ospedaliere, farmacie al dettaglio e altri. Il segmento delle farmacie ospedaliere ha detenuto la quota di mercato più grande nel 2022.
In base al paese, il mercato europeo dell\'epilessia è segmentato in Regno Unito, Germania, Francia, Italia, Spagna e resto d\'Europa. Il Regno Unito ha dominato la quota di mercato dell\'epilessia in Europa nel 2022.
Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc e H. Lundbeck AS sono alcune delle aziende leader che operano nel mercato europeo dell\'epilessia.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation - Overview
4.1.3.1.2 Gene Modulation - Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
4.1.3.1.4 Neuropeptides - Overview
4.1.3.1.5 Engineered Channels - Overview
4.1.3.1.6 Endogenous Channels - Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. Europe Epilepsy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market - Europe Analysis
6.1 Europe: Epilepsy Market
7. Europe Epilepsy Market Analysis - by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Epilepsy Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Epilepsy Market Analysis - by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10. Europe Epilepsy Market Analysis - by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11. Europe Epilepsy Market Analysis - by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12. Europe Epilepsy Market - Country Analysis
12.1 Europe: Epilepsy Market Overview
12.1.1 Europe: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
12.1.1.1 United Kingdom: Epilepsy Market Overview
12.1.1.2 United Kingdom: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 United Kingdom: Epilepsy Market Breakdown, by Type
12.1.1.2.2 United Kingdom: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 United Kingdom: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 United Kingdom: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 United Kingdom: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.3 Germany: Epilepsy Market Overview
12.1.1.4 Germany: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.4.1 Germany: Epilepsy Market Breakdown, by Type
12.1.1.4.2 Germany: Epilepsy Market Breakdown, by Route of Administration
12.1.1.4.3 Germany: Epilepsy Market Breakdown, by Treatment Type
12.1.1.4.4 Germany: Epilepsy Market Breakdown, by Age Group
12.1.1.4.5 Germany: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.5 France: Epilepsy Market Overview
12.1.1.6 France: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.6.1 France: Epilepsy Market Breakdown, by Type
12.1.1.6.2 France: Epilepsy Market Breakdown, by Route of Administration
12.1.1.6.3 France: Epilepsy Market Breakdown, by Treatment Type
12.1.1.6.4 France: Epilepsy Market Breakdown, by Age Group
12.1.1.6.5 France: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.7 Spain: Epilepsy Market Overview
12.1.1.8 Spain: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.8.1 Spain: Epilepsy Market Breakdown, by Type
12.1.1.8.2 Spain: Epilepsy Market Breakdown, by Route of Administration
12.1.1.8.3 Spain: Epilepsy Market Breakdown, by Treatment Type
12.1.1.8.4 Spain: Epilepsy Market Breakdown, by Age Group
12.1.1.8.5 Spain: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.9 Italy: Epilepsy Market Overview
12.1.1.10 Italy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.10.1 Italy: Epilepsy Market Breakdown, by Type
12.1.1.10.2 Italy: Epilepsy Market Breakdown, by Route of Administration
12.1.1.10.3 Italy: Epilepsy Market Breakdown, by Treatment Type
12.1.1.10.4 Italy: Epilepsy Market Breakdown, by Age Group
12.1.1.10.5 Italy: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.11 Rest of Europe: Epilepsy Market Overview
12.1.1.12 Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.12.1 Rest of Europe: Epilepsy Market Breakdown, by Type
12.1.1.12.2 Rest of Europe: Epilepsy Market Breakdown, by Route of Administration
12.1.1.12.3 Rest of Europe: Epilepsy Market Breakdown, by Treatment Type
12.1.1.12.4 Rest of Europe: Epilepsy Market Breakdown, by Age Group
12.1.1.12.5 Rest of Europe: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 CombiGene AB
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 LivaNova Plc
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Novartis AG
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Medtronic Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 GSK Plc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 H. Lundbeck AS
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
?
List of Tables
Table 1. Europe Epilepsy Market Segmentation
Table 2. Cell Therapy Approach - An Overview
Table 3. Gene Therapy Approach - An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
Table 11. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 12. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 13. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 14. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 15. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 17. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 19. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 20. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 21. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 23. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 24. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 25. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 26. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 27. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 28. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 29. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 32. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 33. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 34. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 35. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 36. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 37. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 38. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 39. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 40. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 41. Recent Organic Growth Strategies in Epilepsy Market
Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market
?
List of Figures
Figure 1. Europe Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Europe: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in Epilepsy Market
?
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- CombiGene AB
- LivaNova Plc
- Novartis AG
- Medtronic Plc
- GSK Plc
- H. Lundbeck AS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe epilepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe epilepsy market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.